Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5024048 dose and duration finding with peginterferon alfa-2a and ribavirin in treatment-naive chronic hepatitis C genotype 1 or 4
2008-008258-21Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing RO5024048 + peginterferon alfa-2a + ribavirin with Peginterferon alfa-2a + ribavirin standard of care (2 arms). Primary endpoint: Sustained virologic response at 24 weeks after end of treatment. Started Feb 2009; status: completed.
02
Drugs
mericitabine
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-008258-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008258-21.